Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seock-Ah Im

Showing results (71-80 of 567) with videos related to

Pageof 57
Sort By:
Molecular Cancer Therapeutics|September 17, 2009
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cellsYoung-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, et al.
Cancer Letters|November 16, 2011
Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cellsYoung-Kwang Yoon, Hwang-Phill Kim, Sang-Hyun Song, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 10, 2005
CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experienceDo-Youn Oh, Jee-Hyun Kim, Dong-Wan Kim, et al.
International Journal of Cancer|March 27, 2023
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trialElżbieta Senkus, Suzette Delaloge, Susan M Domchek, et al.
Nutrition and Cancer|June 11, 2016
Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative ChemotherapyDae-Won Lee, Kyung-Hun Lee, Tae-Yong Kim, et al.
Breast Cancer Research and Treatment|August 30, 2020
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinibJi-Yeon Kim, Kyunghee Park, Seock-Ah Im, et al.
BMC Cancer|December 19, 2008
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective studyMi-Jung Kim, Do-Youn Oh, Se-Hoon Lee, et al.
Cancer Letters|February 14, 2013
OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cellsMi-Jung Kim, Hyun-Jin Nam, Hwang-Phill Kim, et al.
International Journal of Oncology|April 30, 2010
DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cellsHeesun Kim, Jinah Park, Yeonjoo Jung, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 24, 2015
Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implicationsChan-Young Ock, Tae-Yong Kim, Kyung-Hun Lee, et al.
Pageof 57

Showing results (71-80 of 567) with videos related to

Sort By:
Pageof 57
Molecular Cancer Therapeutics|September 17, 2009
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cellsYoung-Kwang Yoon, Hwang-Phill Kim, Sae-Won Han, et al.
Cancer Letters|November 16, 2011
Down-regulation of mitogen-inducible gene 6, a negative regulator of EGFR, enhances resistance to MEK inhibition in KRAS mutant cancer cellsYoung-Kwang Yoon, Hwang-Phill Kim, Sang-Hyun Song, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 10, 2005
CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experienceDo-Youn Oh, Jee-Hyun Kim, Dong-Wan Kim, et al.
International Journal of Cancer|March 27, 2023
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trialElżbieta Senkus, Suzette Delaloge, Susan M Domchek, et al.
Nutrition and Cancer|June 11, 2016
Prognostic Role of Body Mass Index in Advanced Small Bowel Adenocarcinoma Patients Receiving Palliative ChemotherapyDae-Won Lee, Kyung-Hun Lee, Tae-Yong Kim, et al.
Breast Cancer Research and Treatment|August 30, 2020
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinibJi-Yeon Kim, Kyunghee Park, Seock-Ah Im, et al.
BMC Cancer|December 19, 2008
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective studyMi-Jung Kim, Do-Youn Oh, Se-Hoon Lee, et al.
Cancer Letters|February 14, 2013
OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cellsMi-Jung Kim, Hyun-Jin Nam, Hwang-Phill Kim, et al.
International Journal of Oncology|April 30, 2010
DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cellsHeesun Kim, Jinah Park, Yeonjoo Jung, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 24, 2015
Metabolic landscape of advanced gastric cancer according to HER2 and its prognostic implicationsChan-Young Ock, Tae-Yong Kim, Kyung-Hun Lee, et al.
Pageof 57